IL2 and acute myeloid leukemia: Later on, 53% complete remission was observed in AML patients treated with haploidentical NK cells combined with an IL-2 diphtheria toxin fusion protein, which was used to deplete host regulatory T cells (107); 32% complete remission was observed in AML patients treated with haploidentical NK cells combined with IL-15 (108), and 44% complete remission was observed in AML patients treated with allogeneic cytokine-induced memory-like NK cells, in separate studies (109).